Preparation method and optimization method of kit for detecting tPAI.C by chemiluminescence method

By using NSP-SA-NHS as acridinyl ester marker and specific buffer formulation, combined with chemiluminescence method, the problem of insufficient stability and accuracy of existing kits for detection of tPAI.C is solved, and the detection time is shortened and the results are achieved. Reliable and low-cost effects.

CN119001087APending Publication Date: 2024-11-22HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410964699.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The current kits for detecting tPAI.C are not very stable and accurate in detection, mainly due to the instability of acridinium ester and buffer, which leads to a long detection time and inaccurate results.

Method used

Using NSP-SA-NHS as acridinyl ester marker, combined with specific buffer formulations (such as tris buffer at pH 8.0±0.1 and MES buffer at pH 6.0±0.1) to improve the stability of labeled antibodies and magnetic microspheres , simplify the detection process, and use chemiluminescence method to replace enzymatic luminescence method to achieve high flash signal intensity and short detection time.

Benefits of technology

It improves the stability and accuracy of detection tPAI.C, shortens the detection time, improves the sensitivity and specificity of the detection, and ensures the reliability and cost-effectiveness of the results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004951394500000021
    Figure BDA0004951394500000021
  • Figure BDA0004951394500000041
    Figure BDA0004951394500000041
  • Figure BDA0004951394500000042
    Figure BDA0004951394500000042
Patent Text Reader

Abstract

The invention provides a preparation method and an optimization method of a kit for detecting tPAI.C by a chemiluminescence method. According to the kit disclosed by the invention, the azine ester which is most stably combined with the tPAI.C antibody is screened out; according to the buffer solution formula provided by the invention, the stability of the tPAI.C antibody marked by the actin in the reagent R1 can be improved, so that the accuracy of the kit for detecting the tPAI.C is improved; the invention provides a buffer solution formula, which can improve the stability of the tPAI.C antibody coated magnetic microspheres in the reagent RM, thereby improving the accuracy of tPAI.C detection by the kit. A chemiluminescence method used by the kit belongs to a flash type instead of an enzymatic luminescence type, and the technical problems of weak signal intensity and long detection time of a luminescence method are solved. The kit for detecting tPAI.C has the advantages of simple operation process, high sensitivity, high accuracy, strong stability, short detection time, reliable result, low cost and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of immunoassay, and specifically relates to a method for preparing a kit for detecting tPAI.C and a method for improving the detection stability and accuracy thereof. Background Art

[0002] Tissue plasminogen activator-plasminogen activator inhibitor-1 complex (tPAI.C) is a complex formed when vascular endothelial cells are damaged and t-PA is released into the blood together with PAI-1. Therefore, the increase of t-PA·PAI-1 complex can be considered to reflect the degree of vascular damage. Clinically, tPAI.C is recognized as a molecular marker that comprehensively reflects the damage of the fibrinolytic system and vascular endothelial cells, indicating that the cause has not been removed or thrombosis is in progress. The tPAI.C content in the blood is one of the best diagnostic indicators for venous thromboembolism (VTE) and a risk indicator for myocardial infarction. It can also determine the degree of repair of the vascular endothelial system after surgery and monitor the effect of thrombosis treatment drugs.

[0003] At present, tPAI.C is mainly detected by enzymatic chemiluminescence. This method has obvious disadvantages. It needs to catalyze the substrate to emit light, and the luminescence speed is slow. It takes a period of incubation reaction for the luminescence to reach the peak, which not only increases the detection steps, but also prolongs the detection time. Its detection stability and accuracy are also poor. Since the content of tPAI.C in blood samples is small and unstable, it needs to be detected in a short time. If the detection time is long, the tPAI.C detection results in blood samples will be inaccurate. The chemiluminescence magnetic bead detection kit combines magnetic separation technology, chemiluminescence technology, and immunoassay technology, and has the advantages of high automation, high sensitivity, and high specificity. The advantage of the acridinium ester marker used is that the labeling is relatively simple, no catalyst or enhancer is required, and the luminescence mechanism is based on the reaction of hydrogen peroxide solution and hydroxide, and the acridinium ester hydrolysis luminescence. Its luminescence can reach a peak in 0.5 seconds, and the luminescence can be completed within 1 second. It is a flash type with low background and high signal-to-noise ratio. This detection method solves the problem of long detection time and has the advantages of high sensitivity, high accuracy, strong stability, short detection time, reliable results and low cost.

[0004] There is no unified testing standard for the kits on the market for detecting tPAI.C, resulting in low stability and accuracy of the kits for detecting tPAI.C. Factors that affect the stability and accuracy of the test include acridinium esters and buffers. Acridinium esters can be divided into two categories, acridinium esters and acridinium sulfonamides, according to the different substituents on their acridinium rings. Different substituents have different stability when combined with labeled antibodies. The type of acridinium ester affects the stability of the reagents, and thus affects the accuracy of the test; the buffer not only preserves the reagents, but also provides a stable environment for detecting tPAI.C. The buffer plays a role in protecting and stabilizing the protein. Buffers with different formulas affect the stability of the reagents, and thus affect the accuracy of the test.

[0005] Therefore, there is an urgent need for a kit for detecting tPAI.C and its application to reduce its detection time and improve detection stability and accuracy. Summary of the invention

[0006] In order to solve the above problems, the present invention provides a method for preparing a kit for detecting tPAI.C by chemiluminescence and an optimization method thereof. The kit of the present invention screens out an acridinium ester that binds most stably to the tPAI.C antibody; the present invention provides a buffer solution formula that can improve the stability of the acridinium ester of the labeled antibody in reagent R1, thereby improving the accuracy of the kit for detecting tPAI.C; the present invention provides a buffer solution formula that can improve the stability of the antibody-coated magnetic microspheres in reagent RM, thereby improving the accuracy of the kit for detecting tPAI.C. The chemiluminescence used in the kit of the present invention belongs to the flash type rather than the enzymatic luminescence type, which solves the technical problems of weak signal intensity and long detection time of the luminescence method. The kit of the present invention for detecting tPAI.C has the advantages of simple operation process, high sensitivity, high accuracy, strong stability, short detection time, reliable results, and low cost.

[0007] On the one hand, the present invention provides a kit for detecting tPAI.C, characterized in that it comprises reagent R1 and reagent RM, wherein R1 comprises a luminescent conjugate solution of a tPAI.C monoclonal antibody labeled with an acridinium ester, wherein the acridinium ester is NSP-SA-NHS, and has the structural formula:

[0008]

[0009] The RM includes a solid phase suspension solution of magnetic particles coated with tPAI.C monoclonal antibody.

[0010] Furthermore, the kit further comprises a buffer of reagent R1, which comprises pH 8.0±0.1, tris, NaCl, Tween, BSA, trehalose, glycine, and proclin 300. The pH 8.0±0.1, tris, and NaCl provide a working environment and play a buffering role, Tween and BSA play a blocking role, reduce background and enhance specific binding, trehalose and glycine play a role of stabilization and protection of proteins, and proclin plays a preservative role.

[0011] Furthermore, the kit also includes a buffer of reagent RM, which includes pH 6.0±0.1, MES, NaCl, Tween, BSA, trehalose, glycine, and proclin 300. The pH 6.0±0.1 and NaCl provide a working environment and play a buffering role, MES plays a role in maintaining the acid-base balance of the solution, Tween and BSA play a blocking role, reduce the background and enhance specific binding, trehalose and glycine play a role in stabilizing and protecting proteins, and proclin 300 plays a preservative role.

[0012] Furthermore, the kit further includes a reagent R2, wherein R2 includes a reagent containing a blocking agent, wherein the reagent includes a buffer solution, and the buffer solution includes pH 6.0±0.1, MES, NaCl, Tween, BSA, trehalose, glycine, and proclin 300. The function of the blocking agent is to block nonspecific reactions and improve the specificity and accuracy of the detection.

[0013] Furthermore, in the kit, the concentration of the acridinium ester-labeled tPAI.C monoclonal antibody in the reagent R1 is 0.08 mg / L, the concentration of the magnetic microspheres coated with the tPAI.C monoclonal antibody in the reagent RM is 0.4 mg / mL, and the concentration of the blocker in the reagent R2 is 0.2 mg / mL.

[0014] Furthermore, the present invention provides a method for preparing a kit for detecting tPAI.C by chemiluminescence method, wherein the kit reagents RM, R1 and R2 are configured after pretreatment, comprising the following steps:

[0015] (1) Preparation of reagent RM: tPAI.C monoclonal antibody-coated magnetic microspheres are diluted to 0.4 mg / mL using reagent RM buffer;

[0016] (2) Preparation of reagent R1: acridinium ester-labeled tPAI.C monoclonal antibody, dilute the acridinium ester-labeled tPAI.C monoclonal antibody to 0.08 mg / L using reagent R1 buffer;

[0017] (3) Preparation of reagent R2: Dilute the blocking agent to 0.2 mg / mL using reagent R2 buffer.

[0018] On the other hand, the present invention provides an acridinium ester for improving the stability and accuracy of detecting tPAI.C, wherein the acridinium ester is NSP-SA-NHS, with the structural formula:

[0019]

[0020] Acridinium compounds are divided into two categories, acridinium esters and acridinium sulfonamides, according to the different substituents on the acridinium ring. They have different stabilities after binding to different antibodies. They are divided into 6 categories, but only 4 of them can be used as chemiluminescent markers. The acridinium ester is DMAE-NHS, and its structural formula is:

[0021]

[0022] NSP-DMAE-NHS, structural formula:

[0023]

[0024] Acridine sulfonamide is NSP-SA-NHS, with the structural formula:

[0025]

[0026] NSP-SA-ADH, structural formula:

[0027]

[0028] These four acridinium esters / acridine sulfonamides are often used as chemiluminescent markers, but their binding abilities to antithrombin antibodies are different. Acridinium esters NSP-DMAE-NHS and DMAE-NHS have acyl and sulfonic acid groups, which can make the luminescence intensity of antibody coupling higher and more stable in buffer; acridinium sulfonamide NSP-SA-NHS has large steric hindrance of sulfonamide and carboxyl structures, good hydrolysis stability, high thermal stability and signal-to-noise ratio; NSP-SA-ADH has a hydrazide group, and its terminal active group reacts with antibodies containing aldehyde groups. The present invention has proved through research that acridinium ester NSP-SA-NHS is more stably bound to tPAI.C monoclonal antibody, which may be related to its sulfonamide and carboxyl binding to antibodies.

[0029] On the other hand, the present invention provides a buffer for improving the stability and detection accuracy of reagent R1, wherein the buffer comprises pH 8.0±0.1, 3.03g / L tris, 8.18g / L NaCl, 5ml / L Tween, 10g / L BSA, 20g / L trehalose, 10g / L glycine, and 1ml / L proclin 300.

[0030] On the other hand, the present invention provides a buffer for improving the stability of reagent RM and the detection accuracy, the buffer comprising pH 6.0±0.1, 19.524g / L MES, 8.18g / L NaCl, 5ml / L Tween, 10g / L BSA, 20g / L trehalose, 10g / L glycine, and 1ml / L proclin 300.

[0031] The present invention provides a method for preparing a kit for detecting tPAI.C and a method for improving the detection stability thereof, which have the following effects:

[0032] 1. The present invention screens out an acridinium ester that can more stably bind to the tPAI.C antibody, prolongs the shelf life of the reagent R1, and thereby improves the stability and accuracy of tPAI.C detection.

[0033] 2. The present invention provides a buffer solution formula that can improve the stability of the acridinium ester labeled antibody in reagent R1, thereby improving the accuracy of the kit in detecting tPAI.C.

[0034] 3. The present invention provides a buffer solution formula that can improve the stability of the antibody-coated magnetic microspheres in the reagent RM, thereby improving the accuracy of the kit in detecting tPAI.C.

[0035] 4. The chemiluminescence used in the kit of the present invention is of the flash type rather than the enzymatic luminescence type, which solves the technical problems of weak signal intensity and long detection time of the luminescence method.

[0036] 5. The present invention provides a method for detecting tPAI.C by using acridinium ester-labeled magnetic microsphere chemiluminescence method, which has the advantages of simple coupling labeling process, high sensitivity, high accuracy, strong stability, short detection time, reliable results, low cost, etc., and plays an important role in clinical detection and medication guidance. DETAILED DESCRIPTION

[0037] The embodiments of the present invention are described in further detail below. It should be noted that the following embodiments are intended to facilitate the understanding of the present invention and do not have any limiting effect thereon. All features disclosed in the embodiments of the present invention, or all steps in the methods or processes disclosed, except for mutually exclusive features and / or steps, can be combined in any manner.

[0038] Example 1: Kit configuration, experimental steps, and precision, linearity, and accuracy assessment

[0039] 1. Pretreatment of reagents, including the following steps:

[0040] The coating of magnetic microspheres includes the following steps:

[0041] (1) 10 mg of magnetic microspheres were taken, magnetically separated, and the solution was removed. The magnetic microspheres were purchased from JSR LifeSciences, with the product number MS300 / Carboxyl;

[0042] (2) taking 1 mL of reaction buffer, oscillating and mixing, removing the solution by magnetic separation, and repeating the washing twice. The reaction buffer is prepared with pH 5.0±0.1 and 10.66 g / LMES;

[0043] (3) Add 1 mg each of EDC and NHS;

[0044] (4) Incubate at room temperature for 30 minutes and remove the solution by magnetic separation;

[0045] (5) Add 1 mL of reaction buffer, shake and mix, remove the solution by magnetic separation, and repeat the washing twice;

[0046] (6) Add 0.1-0.4 mg tPAI.C monoclonal antibody 1 and add reaction buffer to make up to 1 mL. The tPAI.C monoclonal antibody was purchased from Hangzhou Boyin Biotechnology Co., Ltd. with a catalog number of M021901;

[0047] (7) Incubate at room temperature for 2 hours;

[0048] (8) Add 5 mg BSA for blocking, mix well and incubate at room temperature for 3 hours, and remove the solution by magnetic separation;

[0049] (9) Add 1 mL of washing buffer, shake, remove the solution by magnetic separation, and repeat washing 3 times. The washing buffer is prepared by pH 7.3±0.1, 3.0 g / L Tris, 9.0 g / L NaCl, and 1.0 mL / L Tween-20;

[0050] (10) Add 1 mL of preservation solution, remove the solution by magnetic separation, add 1 mL of preservation solution again, dilute to 10 mg / mL magnetic ball solution, and store at 2-8°C. The preservation solution is prepared by pH 7.3±0.1, 3.0 g / L Tris, 9.0 g / L NaCl, 1.0 mL / L Tween-20, 1.0 g / L BSA, and 1.0 mL / L Proclin.

[0051] Acridinium ester labeling of antibodies comprises the following steps:

[0052] (1) Take 0.05 mg of tPAI.C monoclonal antibody 2, dilute the tPAI.C monoclonal antibody to 1 mg / mL with PB buffer 1, add 0.01 mg of acridinium ester, and shake to mix. The tPAI.C monoclonal antibody 2 was purchased from Hangzhou Boyin Biotechnology Co., Ltd. with a catalog number of M021902. The PB buffer 1 consists of pH 8.0±0.1, 1.137 g / L Na2HPO4, and 0.15 g / L NaH2PO4. The acridinium ester was purchased from Suzhou Yaco Company with a catalog number of Y0080.

[0053] (2) The mixture was allowed to react at room temperature for 30 minutes in the dark;

[0054] (3) Add 50 μl of 3% glycine, shake and mix, and then keep the mixture in a dark place at room temperature for 30 minutes;

[0055] (4) Purification was performed using a purified solution of PB buffer 2 through a G-50 chromatography column, and the purified solution was collected by monitoring with a nucleic acid protein analyzer. After collection, the collection volume was calculated, an equal volume of glycerol was added, and the mixture was mixed and stored at -20°C for later use. The PB buffer 2 was prepared with pH 6.5±0.1, 0.382 g / L Na2HPO4, and 0.968 g / L NaH2PO4.

[0056] 2. The configuration of the kit includes the following steps:

[0057] (1) Reagent R1: dilute the labeled tPAI.C acridinium ester antibody to 0.08 mg / L using R1 dilution buffer, mix well, and store at 2-8°C for later use. The R1 dilution buffer is composed of pH 8.0±0.1, 3.03 g / L tris, 8.18 g / L NaCl, 5 ml / L Tween, 10 g / L BSA, 20 g / L trehalose, 10 g / L glycine, and 1 ml / L proclin 300;

[0058] (2) Reagent R2: dilute the blocking agent to 0.2 mg / mL using R2 dilution buffer, wherein the R2 buffer is composed of pH 6.0±0.1, 19.524 g / L MES, 8.18 g / L NaCl, 5 ml / L Tween, 10 g / L BSA, 20 g / L trehalose, 10 g / L glycine, and 1 ml / L proclin 300. The blocking agent is purchased from Hangzhou Boyue Biotechnology Co., Ltd., with a catalog number of HBR-6.

[0059] (3) Reagent RM: Dilute the coated magnetic ball antibody to 0.4 mg / mL using RM dilution buffer, wherein the RM buffer is composed of pH 6.0±0.1, 19.524 g / L MES, 8.18 g / L NaCl, 5 ml / L Tween, 10 g / L BSA, 20 g / L trehalose, 10 g / L glycine, and 1 ml / L proclin 300.

[0060] 3. The steps for quality control product configuration are as follows:

[0061] Configuration of quality control product 1: collect clinical samples, use contrast reagent (assignment of tissue plasminogen activator-inhibitor 1 complex chemiluminescence detection kit produced by Sysmex) to select samples near the target concentration and mix them to obtain samples within the required concentration range. The concentration range of quality control product 1 is 6.00-10.00 ng / mL; or purchase commercial tPAI.C antigen (antigen purchased from Hangzhou Boyin Biotechnology Co., Ltd., item number R021901), and dilute it to 6.00-10.00 ng / mL with bovine serum. The theoretical concentration of quality control product 1 is 8.4 ng / mL.

[0062] Configuration of quality control product 2: collect clinical samples, assign values ​​with contrast reagent (tissue plasminogen activator-inhibitor 1 complex chemiluminescence detection kit produced by Sysmex, select samples near the target concentration for mixing, obtain samples within the required concentration range, the concentration range of quality control product 2 is 30.00-70.00 ng / mL; or purchase commercial tPAI.C antigen (antigen purchased from Hangzhou Boyin Biotechnology Co., Ltd., item number R021901), and dilute with bovine serum to 30.00-70.00 ng / mL. The theoretical concentration of quality control product 2 is 45.3 ng / mL.

[0063] 4. The kit detection process includes the following steps:

[0064] (1) Place the reagents into a fully automatic chemiluminescence immunoassay analyzer, place the sample in a sample rack and place it into the instrument, and set the test task. The fully automatic chemiluminescence instrument was purchased from Coleus Biotechnology (Chongqing) Co., Ltd., model Venus100S;

[0065] (2) The instrument automatically takes 10 μL of the sample into the reaction cup, and then adds 50 μL of reagent R2 and 50 μL of RM in sequence, and mixes well;

[0066] (3) Add 100 μL of reagent R1, mix well, incubate at 37°C for 5 minutes, and perform magnetic separation and washing three times, wherein the washing solution is PBS;

[0067] (4) Add 100 μL of substrate A and 100 μL of substrate B, and detect the luminescent signal. The substrate A is hydrogen peroxide purchased from Feipeng Biotechnology Co., Ltd. with a product number of CE00001F11, and the substrate B is sodium hydroxide purchased from Feipeng Biotechnology Co., Ltd. with a product number of CE00001F12.

[0068] 6. Kit performance evaluation

[0069] (1) Precision evaluation

[0070] According to the above 4 test procedures of the test kit, quality control product 1 and quality control product 2 were tested 10 times, and their mean, standard deviation STD and coefficient of variation CV were calculated according to the test results. The experimental results are shown in Table 1 below.

[0071] Table 1. Repeated test results of quality control product concentration

[0072]

[0073] According to the experimental results in Table 1, the kit of the present invention controls the standard deviation of quality control product 1 within 0.3, and the standard deviation of quality control product 2 within 1.0, both less than 3.0, indicating that the data stability is good; the coefficient of variation of quality control product 1 and quality control product 2 is controlled within 3%, and both are controlled within 5%, which shows that although the data has a certain degree of discreteness, this discreteness is reliable from the perspective of the credible limit specified by the standard deviation. It can be seen that the precision of the kit is good.

[0074] (2) Linear performance evaluation

[0075] The high-value analyte close to 100.00 ng / mL and the low-value analyte close to 1.00 ng / mL were diluted and mixed into 6 dilution concentrations according to a certain ratio. The dilution ratios are as follows:

[0076] Sample No. Linear 1 Linear 2 Linear 3 Linear 4 Linear 5 Linear 6 Low value analyte 1 0.9 0.8 0.5 0.25 0 High value analytes 0 0.1 0.2 0.5 0.75 1

[0077] Each linear sample was tested three times, the average was taken and compared with the theoretical value, and the correlation coefficient (r) of linear regression was calculated. The experimental results are shown in Table 2 below.

[0078] Table 2. Detection of linear samples 1-5 by the kit

[0079]

[0080] The results in Table 2 show that the linear correlation coefficient between the linear sample concentration detected by the kit and the theoretical concentration can reach above 0.99, indicating that the concentration detected by the kit of the present invention is very close to the theoretical value. It can be seen that the kit has good linear performance within the detection range.

[0081] (3) Accelerated thermal stability test

[0082] According to the Arrhenius formula, 7 days of acceleration at 37°C can simulate storage in a 2-8°C environment for about 12 months, and 14 days of acceleration at 37°C can simulate storage in a 2-8°C environment for about 24 months. Quality control product 1 and quality control product 2 were accelerated in a 37°C environment, and the signal values ​​of the two quality control products were detected on days 0, 3, 7, 10, 14, and 15 according to the kit detection process described in Example 1. Day 0 was used as the control, and the deviation of the measured values ​​before and after acceleration was compared. The experimental results are shown in Table 3 below.

[0083] Table 3. Test kit thermal stability test results

[0084]

[0085] According to the results in Table 3, the overall 37°C accelerated stability of the kit has a deviation of less than 10% within 14 days, and the 0-day accelerated result has a very small deviation from the control, indicating that the kit not only has good stability but also has high detection accuracy. It can be inferred that the reagent can be stored for 24 months at 2-8°C.

[0086] Example 2: Effects of different acridinium esters / acridine sulfonamides on the assay

[0087] There are four commonly used acridinium esters or acridinium sulfonamides for chemiluminescence. The acridinium ester is NSP-DMAE-NHS, with the structural formula:

[0088]

[0089] DMAE-NHS, its structural formula:

[0090]

[0091] Acridine sulfonamide has NSP-SA-NHS, structural formula:

[0092]

[0093] NSP-SA-ADH, structural formula:

[0094]

[0095] Acridinium esters NSP-DMAE-NHS and DMAE-NHS have acyl and sulfonic acid groups, which can make the antibody coupling luminescence intensity higher and more stable in the buffer; acridinium sulfonamide NSP-SA-NHS has large steric hindrance of sulfonamide and carboxyl structures, good hydrolysis stability, thermal stability and high signal-to-noise ratio; NSP-SA-ADH has a hydrazide group, and its terminal active group reacts with antibodies containing aldehyde groups. These two categories are commonly used markers in chemiluminescent immunoassays. The experiment was designed to screen out the acridinium ester that binds most stably to tPAI.C monoclonal antibody. The screening experiment method is as follows:

[0096] The four acridinium esters NSP-DMAE-NHS, DMAE-NHS, NSP-SA-NHS, and NSP-SA-ADH were used to prepare reagent R1 containing different acridinium esters according to the labeling method of acridinium esters described in Example 1, and the acridinium esters were evaluated for accelerated stability at 37°C. NSP-DMAE-NHS, DMAE-NHS, and NSP-SA-NHS were purchased from Suzhou Yaco, and NSP-SA-ADH was purchased from Hubei Xindesheng Materials Technology Co., Ltd. According to the Arrhenius formula, 7 days of acceleration at 37°C can simulate storage in a 2-8°C environment for about 12 months, and 14 days of acceleration at 37°C can simulate storage in a 2-8°C environment for about 24 months. Two reagents R1 containing different acridinium esters were accelerated in a 37°C environment. The concentrations of the two quality control products were detected on days 0, 3, 7, 10, 14 and 15 according to the detection process described in Example 1. The theoretical concentration of the quality control product was used as a control to compare the measured value deviations before and after acceleration. The experimental results are shown in Tables 4, 5, 6 and 7 below.

[0097] Table 4. Effect of 37℃ accelerated experiment on NSP-DMAE-NHS

[0098]

[0099] Table 5. Effect of 37℃ accelerated test on DMAE-NHS

[0100]

[0101] Table 6. Effect of 37℃ accelerated test on NSP-SA-NHS

[0102]

[0103] Table 7. Effect of 37℃ accelerated experiment on NSP-SA-ADH

[0104]

[0105] According to the results in Tables 4, 5, 6 and 7, under the same labeling process and buffer conditions, the overall deviation between NSP-SA-NHS and the control is significantly smaller than that of the other three acridinium esters in the range of 0 to 15 days, indicating that it is stably bound to the calibrated antithrombin antibody and is not easy to fall off. It is speculated that its sulfonamide and carboxyl structures play a stabilizing role, while the acyl and sulfonic acid groups of NSP-DMAE-NHS and DMAE-NHS are not as stable as those of NSP-SA-NHS, and NSP-SA-ADH may be unstable in binding to tPAI.C monoclonal antibody due to the terminal active group; and at 0 days of acceleration, the deviation between NSP-SA-NHS and the control is much smaller than that of the other three acridinium esters, which shows that the accuracy of using NSP-SA-NHS as a chemiluminescent marker is higher. Therefore, NSP-SA-NHS is selected as the labeling raw material.

[0106] Example 3: Screening of dilution buffer for reagent R1

[0107] According to Example 2, based on the use of NSP-SA-NHS, the effect of R1 buffer on the kit determination was explored, and the optional buffer formulas are shown in Table 8 below.

[0108] Table 8. Reagent R1 dilution buffer formula

[0109]

[0110] The experimental method refers to the accelerated thermal stability experiment in Example 1, and the theoretical concentration value of the quality control product is used as a control. The experimental results are shown in Tables 9, 10, and 11 below.

[0111] Table 9. Effect of buffer formula 1 on reagent R1

[0112]

[0113] Table 10. Effect of buffer formula 2 on reagent R1

[0114]

[0115] Table 11. Effect of buffer formula 3 on reagent R1

[0116]

[0117] According to the analysis of Tables 9 and 10, Formula 2 has one more glycine than Formula 1. When the acceleration is 7 days, the deviations of both formulas from the control are controlled within 10%, and when the acceleration is 10 days, the deviation of Formula 2 from the control is significantly smaller than that of Formula 1. It is speculated that glycine has the effect of improving the stability of tPAI.C monoclonal antibody. According to the analysis of Tables 10 and 11, the difference between Formula 3 and Formula 2 lies in the sugar. When the acceleration is 7 days, the deviations of both formulas from the control are controlled within 5%, which is not much different. However, when the acceleration is 15 days, Formula 3 can still be controlled within 10%, indicating that trehalose has a greater effect on improving the stability of tPAI.C monoclonal antibody than sucrose. When the acceleration is 0 days, the deviation of Formula 3 from the control is much smaller than that of Formula 2 and Formula 1, indicating that Formula 3 is not only stable, but also accurate. In summary, Formula 3 is selected as the dilution buffer of reagent R1.

[0118] Based on the above experimental results, it is speculated whether different salt buffer systems and different amino acids / proteins will affect the test results of the kit. The available salt buffer systems are tris buffer system and phosphate buffer system, and the available amino acids / proteins are glycine and Casein. To verify the hypothesis, different system buffers are configured as shown in Table 12 below.

[0119] Table 12. Buffer formulations for different salt buffer systems and different amino acid / protein combinations

[0120]

[0121] The experimental method refers to the accelerated thermal stability experiment in Example 1, and the results on day 0 and day 7 are tested, with the theoretical concentration value of the quality control product as the control. The experimental results are shown in Table 13 below.

[0122] Table 13. Experimental results of different salts and different amino acid / protein formulas

[0123]

[0124] According to the results in Table 13, the deviations of Formulas 1, 2, 3, and 4 from the control after 7 days of acceleration were all controlled within 10%, but Formula 1 had a smaller deviation from the control than Formulas 2, 3, and 4, especially when accelerated for 7 days, the deviation from the control was much smaller than that of other formulas, indicating that Formula 1 had the best stability. At 0 days of acceleration, the deviation from the control of Formula 1 was also much smaller than that of other formulas, indicating that it not only had high stability but also high accuracy. In summary, the combination of tris buffer and glycine was selected as the buffer formula of reagent R1.

[0125] Example 4: Screening of reagent RM dilution buffer

[0126] To investigate the effect of RM buffer on the assay of the kit, the available buffer formulas are shown in Table 14.

[0127] Table 14. Reagent RM dilution buffer formula

[0128]

[0129] The experimental method refers to Example 3, with the theoretical concentration value of the quality control product as the control. The experimental results are shown in Tables 15, 16 and 17 below.

[0130] Table 15. Effect of Formula 1 on Reagent RM

[0131]

[0132] Table 16. Effect of Formula 2 on Reagent RM

[0133]

[0134] Table 17. Effect of Formula 3 on Reagent RM

[0135]

[0136] Formulas 1, 2, and 3 have only one different substance, namely tris, citric acid, and MES, which are all commonly used solvents for buffers. According to the results of Tables 15, 16, and 17, the deviations of Formulas 1, 2, and 3 from the control were controlled within 10% when accelerated for 10 days, but only Formula 3 was controlled within 10% from the control when accelerated for 15 days, indicating that MES has a stronger effect on improving the stability of the reagent RM than tris and citric acid. It is speculated that MES interacts with the peptide backbone of bovine serum albumin and can increase the stability of the antibody protein. And at 0 days of acceleration, the deviation of Formula 3 from the control is much smaller than that of Formula 2 and Formula 1, indicating that Formula 3 is not only highly stable, but also highly accurate. In summary, Formula 3 was selected as the dilution buffer for the reagent RM.

[0137] According to the above experimental results, it is speculated whether different sugars and different amino acids / proteins will affect the test results of the kit. The available sugars are trehalose and sucrose, and the available amino acids / proteins are glycine and Casein. To verify the hypothesis, different system buffers are configured as shown in Table 18 below.

[0138] Table 18. Buffer formulations for different sugars and different amino acid / protein combinations

[0139]

[0140] The experimental method refers to the accelerated thermal stability experiment in Example 1, and the theoretical concentration value of the quality control product is used as a control to detect the results on the 0th day and the 7th day. The experimental results are shown in Table 19 below.

[0141] Table 19. Experimental results of different sugars and different amino acid / protein formulas

[0142]

[0143] It can be seen from the two-by-two combinations of different sugars and Casein / glycine at 0 days of acceleration that the experimental results of the two combinations of trehalose and glycine in formula 1 and trehalose and Casein in formula 2 have a small deviation from the control, especially the trehalose and glycine combination in formula 1, indicating that these two combinations have a high accuracy in detecting tPAI.C as buffer components. However, at 7 days of acceleration, the deviation between the trehalose and glycine combination in formula 1 and the control is much smaller than that of other combinations, indicating that this combination has the best stability. In summary, the combination of trehalose and glycine in formula 1 as a component of the buffer is not only accurate but also stable. Therefore, trehalose and glycine are selected as raw materials for configuring the reagent RM buffer.

[0144] The application of the present invention is not limited thereto. For example, the scope of application of the present invention can be expanded according to the environmental protection aspect. Any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the scope defined by the claims.

Claims

1. A kit for detecting tPAI.C, characterized in that: It includes reagent R1 and reagent RM, wherein R1 includes a luminescent conjugate solution of tPAI.C monoclonal antibody labeled with acridinium ester, wherein the acridinium ester is NSP-SA-NHS, and has the structural formula: The RM includes a solid phase suspension solution of magnetic particles coated with tPAI.C monoclonal antibody.

2. The kit according to claim 1, characterized in that The reagent R1 also includes a buffer solution, wherein the buffer solution includes pH 8.0±0.1, tris, NaCl, Tween, BSA, trehalose, glycine, and proclin300.

3. The kit according to claim 2, characterized in that Also included is a buffer of reagent RM, which includes pH 6.0±0.1, MES, NaCl, Tween, BSA, trehalose, glycine, and proclin300.

4. The kit according to claim 3, characterized in that The reagent R2 is also included, and the R2 includes a solution of a blocking agent. The R2 also includes a buffer solution, and the buffer solution includes pH 6.0±0.1, MES, NaCl, Tween, BSA, trehalose, glycine, and proclin 300.

5. The kit according to claim 4, characterized in that The concentration of the acridinium ester-labeled tPAI.C monoclonal antibody in the reagent R1 is 0.08 mg / L, the concentration of the magnetic microspheres coated with the tPAI.C monoclonal antibody in the reagent RM is 0.4 mg / mL, and the concentration of the blocking agent in the reagent R2 is 0.2 mg / mL.

6. A method for detecting tPAI.C by magnetic microsphere chemiluminescence, characterized in that: The detection is performed using the kit as described in any one of claims 1 to 5.

7. The kit according to claim 6, characterized in that The reagents RM, R1 and R2 of the kit are configured after pre-treatment, including the following steps: (1) Preparation of reagent RM: tPAI.C monoclonal antibody-coated magnetic microspheres are diluted to 0.4 mg / mL using reagent RM buffer; (2) Preparation of reagent R1: acridinium ester-labeled tPAI.C monoclonal antibody, dilute the acridinium ester-labeled tPAI.C monoclonal antibody to 0.08 mg / L using reagent R1 buffer; (3) Preparation of reagent R2: Dilute the blocking agent to 0.2 mg / mL using reagent R2 buffer.

8. An acridinium ester for improving the stability and accuracy of detecting tPAI.C, characterized in that: The acridinium ester is NSP-SA-NHS, with the structural formula:

9. A buffer solution is used to improve the stability and detection accuracy of reagent R1, characterized in that: The buffer includes pH 8.0±0.1, 3.03 g / L tris, 8.18 g / L NaCl, 5 ml / L Tween, 10 g / L BSA, 20 g / L trehalose, 10 g / L glycine, and 1 ml / L proclin 300.

10. A buffer for improving the stability and detection accuracy of a reagent RM, characterized in that: The buffer includes pH 6.0±0.1, 19.524 g / L MES, 8.18 g / L NaCl, 5 ml / L Tween, 10 g / L BSA, 20 g / L trehalose, 10 g / L glycine, and 1 ml / L proclin 300.

Citation Information

Cited By

  • Composition, reagent, kit, application of composition in detection of PCT and IL-6 and detection method of PCT and IL-6

    CN120214332A

  • Composition, reagent, kit and use thereof in PCT and IL-6 detection and PCT and IL-6 detection method

    CN120214332B